Biotech News

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

Catalyst Biosciences (CBIO)Catalyst Biosciences2026-08-07 11:00 ESTEarnings

Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026 SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc.

Related news

CBIOCatalyst Biosciences2025-11-07 11:00 EST

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

CBIOCatalyst Biosciences2026-03-12 10:00 EST

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

View all latest news

Catalyst Biosciences

Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.

Recent company news

CBIOCatalyst Biosciences2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

CBIOCatalyst Biosciences2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

CBIOCatalyst Biosciences2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

CBIOCatalyst Biosciences2026-05-07 10:00 EST

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

CBIOCatalyst Biosciences2026-05-04 12:48 EST

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Stock data

Close: 17.15 USD
Market cap: 468.91M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States